Lisa M. Meeks, PhD and Christopher Moreland, MD, MPH
Obstacles for applicants with disabilities illuminate admission practices that could help craft a clinical workforce that is appropriately diverse and prepared to give just, patient-centered care.
AMA J Ethics. 2021;23(12):E987-994. doi:
10.1001/amajethics.2021.987.
Dr Lisa M. Meeks joins Ethics Talk to discuss her article, coauthored with Dr Christopher Moreland: “How Should We Build Disability-Inclusive Medical School Admissions?”
Dr Matthew K. Wynia joins Ethics Talk to discuss his article, coauthored with Dr Robert Baker: “Living Histories of Structural Racism and Organized Medicine”
Dr Dorothy W. Tolchin joins Ethics Talk to discuss her article, coauthored with Nicole D. Agaronnik, Shahin A. Saberi, and Dr Michael Ashley Stein: “Why Disability Must Be Included in Medical School Diversification Efforts”
Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021;23(7):E569-575. doi:
10.1001/amajethics.2021.569.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"